1. Center for Drug Evaluation and Research. Drug-induced liver injury: premarketing clinical evaluation [Internet]. Silver Spring (MD): U.S. Food and Drug Administration (USFDA); 2009. [cited 2023 May 10]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-induced-liver-injury-premarketing-clinical-evaluation.
2. FDA-NIH Biomarker Working Group. BEST (biomarkers EndpointS and other tools) resource (Internet). Silver Spring (MD): U.S. Food and Drug Administration (USFDA); 2016–20. Glossary. 2016 Jan 28. Updated 2020 Mar 3. (Webpage)
3. Council for International Organisations of Medical Sciences. Drug-induced liver injury (DILI): current status and future directions for drug development and the post-market setting; 2020.
4. Critical Path Institute (C-Path) Predictive Safety Testing Consortium’s (PSTC) Hepatocyte Working Group (HWG). Qualification plan for glutamate dehydrogenase (GLDH) as a biomarker of drug induced liver injury in individuals with skeletal muscle degeneration; 2020.
5. The past and present of serum aminotransferases and the future of liver injury biomarkers;McGill MR.;EXCLI J,2016